🇺🇸 FDA
Pipeline program

ProHema-CB

FT1050-03

Phase 2 mab terminated

Quick answer

ProHema-CB for Hematologic Malignancies is a Phase 2 program (mab) at FATE THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
FATE THERAPEUTICS INC
Indication
Hematologic Malignancies
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials